Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598517 | 0.82 | ADK (0.47) | GRM5MAPTAPPPDGFRBPDGFRA | |
| SCHEMBL23283107 | 0.79 | GRM5 (0.49) | GRM5MAPTAPPPDGFRBPDGFRA | |
| SCHEMBL23283119 | 0.78 | ADK (0.43) | GRM5FFAR1ADK | |
| SCHEMBL18952096 | 0.76 | MAP4K3 (0.47) | GRM5MAPTAPPGRM4FFAR1 | |
| SCHEMBL19872574 | 0.76 | BRAF (0.36) | GRM5 | |
| SCHEMBL20915840 | 0.75 | NOS3 (0.34) | GRM5 | |
| SCHEMBL16598714 | 0.75 | APP (0.52) | MAPTAPPGRM4FFAR1FFAR4 | |
| SCHEMBL23283151 | 0.75 | GRM5 (0.56) | GRM5APPPDGFRBPDGFRAGRM4 | |
| SCHEMBL29952740 | 0.75 | GRM5 (0.42) | GRM5MAPTAPPPDGFRBPDGFRA | |
| SCHEMBL13388284 | 0.75 | FFAR1 (0.51) | GRM5GRM4FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048659-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021080013-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021080015-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-04-29 | — | — | WO | disclosed |
| US-9676732-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3049409-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114028-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3049409-A1 | ETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20160207890-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| EP-2493856-B1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN LA ROCHE (CH) | 2016-04-27 | — | — | EP | disclosed |
| WO-2015044075-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-02 | — | — | WO | disclosed |
| US-8716316-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130131056-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2493856-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. Hoffmann-La Roche AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | GRM5 1/4885MAPT 1274/4885APP 2560/4885 |
| US-20130131056-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | GRM5 1/4885MAPT 1274/4885APP 2560/4885 |
| US-20160207890-A1 | ETHYNYL DERIVATIVES | GRM2, GRIA4, GRM4 | GRM5 15/4885MAPT 2412/4885APP 2144/4885 |
| US-20170114028-A1 | ETHYNYL DERIVATIVES | GRM2, GRIA4, GRM4 | GRM5 15/4885MAPT 2412/4885APP 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.